A/Prof. Joel Castro Kraftchenko (published as Joel Castro) is a Research Associate Professor in Neuroscience and Principal Investigator at the Gut Sensory Systems Research Group, Flinders Health and Medical Research Institute (FHMRI). A recognised leader in endometriosis and chronic gut disorders like IBS and IBD, his pre-clinical and translational science focuses on developing targeted treatments for chronic pelvic and visceral pain.
His research excellence is demonstrated by 66 published articles—including high-impact papers in Nature (x4), Cell, Science, Pain (x7), and Gut (x4)—generating over 61,000 citations with an h-index of 40. As Chief Investigator A, he has secured two recent NHMRC Ideas Grants (GNT1191448 and GNT2029332) to advance these programs.
Dr. Castro’s work has a proven track record of clinical and commercial translation, notably contributing to the FDA approval of Linaclotide with Ironwood Pharmaceuticals. He is currently evaluating a clinically approved monoclonal antibody for endometriosis pain, protected by international patent PCT/EP2024/054990 ("Anti-netrin-1 monoclonal antibody for treating endometriosis and associated pains"), with clinical trials scheduled for 2027.
His global research network spans elite industry partners like Takeda, GSK, and Arena Pharmaceuticals, alongside major national and international institutions including the Robinson Research Institute, the Royal Women’s Hospital Melbourne, the Cancer Research Centre of Lyon, Harvard, Cambridge, and Johns Hopkins University.